Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × lorlatinib × Lymphoid × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 17 Tumor-Agnostic 1 Lymphoid 1

Conditions

Recurrence 1 Lymphoma, Large-Cell, Anaplastic 1

Interventions

Rituximab 627 Cyclophosphamide 546 Vincristine 251 Etoposide 245 Doxorubicin 242 Cytarabine 203 Prednisone 201 Methotrexate 189 Filgrastim 168 Dexamethasone 163 fludarabine phosphate 161 fludarabine 157 Lenalidomide 148 Radiotherapy 118 Melphalan 112 Peripheral Blood Stem Cell Transplantation 107 Busulfan 105 Bendamustine Hydrochloride 105 Bortezomib 101 ibrutinib 100 Mycophenolic Acid 96 Granulocyte Colony-Stimulating Factor 96 venetoclax 94 Whole-Body Irradiation 92 obinutuzumab 91 Tacrolimus 86 Gemcitabine 83 zanubrutinib 75 Alemtuzumab 66 Carmustine 65

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03505554 2023-08-07

CRU3

University of Milano Bicocca

Phase 2 Unknown

Recurrence, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡